Biorchestra announces US$45 million series C fundraising

he financing was significantly oversubscribed with high demand from both existing and new investors.

Vicore advances on new chemical entity from VP03 program

Four additional AT2R agonists are expected to finalize preclinical evaluation during 2022

Bayer highlights pharma business plans on Media Day

Robust pipeline with around 50 projects in clinical development / cardiology portfolio poised for growth with launch products Kerendia (finerenone) and Verquvo (vericiguat)

Velocity Clinical Research invests in Indian tech, acquires TrierHealth

The investment in Indian clinical technology expertise in Hyderabad comes amid the clinical trials sector's move towards decentralised trials

Daewoong Pharmaceutical posts strong financials in 2021

Daewoong delivered KRW 1.055 trillion in sales, KRW 95.5 billion in operating profit and KRW 40.5 billion in net profit.

Prestige BioPharma’s Tuznue receives EU-GMP certification

Prestige BioPharma’s facility receives EU-GMP certification

The facility will manufacture its Herceptin biosimilar, Tuznue

AstraZeneca partners with Honeywell to develop next-gen respiratory inhalers

New inhalers would have near-zero Global Warming Potential propellant

CanSinoBIO's Convidecia approved as heterologous booster in China

Heterologous booster vaccination refers to the use of vaccine boosters from different technology platforms from the prime vaccines, which could improve the overall immune response and enhance protection against other variants

Enhertu Phase III results to redefine how metastatic breast cancer is classifed

Enhertu is a HER2-directed antibody drug conjugate (ADC) being jointly developed by AstraZeneca and Daiichi Sankyo.